Zhihua Li

List of Publications by Year
in descending order

29 papers	1,609 citations	361413 20 h-index	454955 30 g-index
30 all docs	30 docs citations	30 times ranked	2371 citing authors

#	Article	IF	Citations
1	The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. Journal of Translational Medicine, 2015, 13, 84.	4.4	211
2	LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9. Cancer Letters, 2017, 410, 68-81.	7.2	161
3	Tumor-associated macrophages promote progression and the Warburg effect via CCL18/NF-kB/VCAM-1 pathway in pancreatic ductal adenocarcinoma. Cell Death and Disease, 2018, 9, 453.	6.3	160
4	Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsaâ€miRâ€29bâ€3p in pancreatic ductal adenocarcinoma. Journal of Cellular and Molecular Medicine, 2018, 22, 655-667.	3.6	116
5	Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. Cell Death and Disease, 2018, 9, 1065.	6.3	106
6	Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers. Oncotarget, 2015, 6, 35684-35698.	1.8	85
7	Inhibition of glutamine metabolism counteracts pancreatic cancer stem cell features and sensitizes cells to radiotherapy. Oncotarget, 2015, 6, 31151-31163.	1.8	76
8	Glutamate dehydrogenase is a novel prognostic marker and predicts metastases in colorectal cancer patients. Journal of Translational Medicine, 2015, 13, 144.	4.4	70
9	Endogenous miRNA Sponge LincRNA-ROR promotes proliferation, invasion and stem cell-like phenotype of pancreatic cancer cells. Cell Death Discovery, 2017, 3, 17004.	4.7	60
10	circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis. Molecular Cancer, 2022, 21, 24.	19.2	60
11	Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in a TNFRSF10A-related manner. Cancer Letters, 2016, 371, 354-365.	7.2	56
12	The long non-coding RNA HOTAIR affects the radiosensitivity of pancreatic ductal adenocarcinoma by regulating the expression of Wnt inhibitory factor 1. Tumor Biology, 2016, 37, 3957-3967.	1.8	54
13	Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients. Cancer Science, 2018, 109, 199-206.	3.9	50
14	FEZF1-AS1/miR-107/ZNF312B axis facilitates progression and Warburg effect in pancreatic ductal adenocarcinoma. Cell Death and Disease, 2018, 9, 34.	6.3	48
15	Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-Î²1/smad2/3 axis in pancreatic cancer. Cancer Letters, 2019, 459, 204-215.	7.2	48
16	Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells. Oncology Reports, 2012, 27, 1879-86.	2.6	35
17	Metabolic Phenotypes in Pancreatic Cancer. PLoS ONE, 2015, 10, e0115153.	2.5	34
18	<scp>HIF</scp>â€2Î± regulates nonâ€canonical glutamine metabolism <i>via</i> activation of <scp>PI</scp>3K/<scp>mTORC</scp>2 pathway in human pancreatic ductal adenocarcinoma. Journal of Cellular and Molecular Medicine, 2017, 21, 2896-2908.	3.6	25

#	Article	IF	Citations
19	circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-ıºB signaling pathway. Journal of Experimental and Clinical Cancer Research, 2022, 41, 71.	8.6	25
20	A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases. International Journal of Surgery, 2016, 29, 108-117.	2.7	22
21	Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair. Oncogene, 2022, 41, 2372-2389.	5.9	21
22	PDâ€L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced nonâ€small cell lung cancer?. Journal of Gene Medicine, 2021, 23, e3294.	2.8	14
23	A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study. British Journal of Cancer, 2021, 125, 402-412.	6.4	7
24	Neoadjuvant camrelizumab, nab-paclitaxel, and carboplatin in patients with stage IB-IIIA non-small cell lung cancer (NANE-LC): a study protocol of prospective, single-arm, multicenter, phase II study. Journal of Thoracic Disease, 2021, 13, 6468-6475.	1.4	5
25	Nanocomplexation of thrombin with cationic amylose derivative for improved stability and hemostatic efficacy. International Journal of Nanomedicine, 2015, 10, 939.	6.7	4
26	Novel bloodâ€based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in nonâ€smallâ€cell lung cancer: Results from two multicenter, randomized clinical trials. Clinical and Translational Medicine, 2020, 10, e53.	4.0	2
27	Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis. Annals of Hematology, 2022, 101, 595-605.	1.8	2
28	A phase 1b/2 trial of SHR-1701 in combination with gemcitabine and nab-paclitaxel in patients with untreated locally advanced or metastatic pancreatic cancer.. Journal of Clinical Oncology, 2022, 40, e16264-e16264.	1.6	2
29	Gemcitabine plus cisplatin (GP) versus 5-FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III trial.. Journal of Clinical Oncology, 2016, 34, 6007-6007.	1.6	1